Ibrance

Swallow whole. Take caps (with food); tabs (with or without food). 125mg once daily for 21 consecutive days followed by 7 days off to complete a 28-day cycle, in combination with an aromatase inhibitor or with fulvestrant 500mg on Days 1, 15, 29, and once monthly thereafter (see each drug's full labeling for dosing/duration). In the combination with fulvestrant therapy: pre/perimenopausal women should be treated with LHRH agonists according to clinical standards. In the combination with aromatase inhibitor therapy for men: consider LHRH agonist. Dose modification for adverse reactions: First reduction: 100mg/day; Second dose reduction: 75mg/day; discontinue if <75mg/day required. Dose modification for hematologic or non-hematologic toxicities: see full labeling. Concomitant strong CYP3A inhibitors: avoid and consider alternative drug; if use necessary, reduce palbociclib dose to 75mg/day. Severe hepatic impairment (Child-Pugh Class C): 75mg once daily for 21 consecutive days followed by 7 days off to complete a 28-day cycle.